Literature DB >> 33512475

International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey.

David T Rubin1, Charles Sninsky2, Britta Siegmund3, Miquel Sans4, Ailsa Hart5, Brian Bressler6, Yoram Bouhnik7, Alessandro Armuzzi8, Anita Afzali9.   

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD), including Crohn disease (CD) and ulcerative colitis (UC), are complex disorders with multiple comorbidities. We conducted international patient and physician surveys to evaluate current experiences and perceptions of patients with CD or UC and physicians who treat IBD.
METHODS: The IBD Global Assessment of Patient and Physician Unmet Need Surveys comprised a patient survey and a physician survey, fielded in North America and Europe between August 16, 2019, and November 10, 2019. Adults with CD or UC (targeted 1:1 ratio) were recruited from physicians, patient advocacy groups, and recruitment panels; physicians were recruited by recruitment agencies and panels.
RESULTS: In total, 2398 patients with IBD (1368 CD, 1030 UC) and 654 physicians completed surveys. Anxiety and depression were the most common comorbidities among patients with IBD. Patients and physicians were generally aligned on treatment goals and patient-physician communication. Patients with IBD reported high quality-of-life impact by rectal urgency and need to use the toilet, which were rated as lower-impact by physicians. Patients defined remission based on symptoms; physicians defined remission based primarily on clinical tests. Patients expected current treatments to control their disease for a longer duration than did physicians. Patients expressed more concern about corticosteroid use compared with physicians; many physicians reported prescribing corticosteroids for more than 4 months per year in some patients.
CONCLUSIONS: Patients could benefit from education about disease remission and expectations for current therapies. High corticosteroid use is concerning to patients, and physicians should minimize the use of corticosteroids for extended periods of time.
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Entities:  

Keywords:  Crohn disease; inflammatory bowel disease; ulcerative colitis

Mesh:

Substances:

Year:  2021        PMID: 33512475      PMCID: PMC8637792          DOI: 10.1093/ibd/izab006

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  30 in total

Review 1.  Long-term side effects of glucocorticoids.

Authors:  Merih Oray; Khawla Abu Samra; Nazanin Ebrahimiadib; Halea Meese; C Stephen Foster
Journal:  Expert Opin Drug Saf       Date:  2016-02-06       Impact factor: 4.250

2.  Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.

Authors:  Mark Löwenberg; Severine Vermeire; Nahid Mostafavi; Frank Hoentjen; Denis Franchimont; Peter Bossuyt; Pieter Hindryckx; Theo Rispens; Annick de Vries; C Janneke van der Woude; Sophie Berends; Carmen A Ambarus; Ron Mathot; Esme Clasquin; Filip Baert; Geert D'Haens
Journal:  Gastroenterology       Date:  2019-06-05       Impact factor: 22.682

Review 3.  Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.

Authors:  Dong Yeon Jeong; Seung Kim; Min Ji Son; Chei Yun Son; Jong Yeob Kim; Andreas Kronbichler; Keum Hwa Lee; Jae Il Shin
Journal:  Autoimmun Rev       Date:  2019-03-04       Impact factor: 9.754

4.  Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015.

Authors:  James M Dahlhamer; Emily P Zammitti; Brian W Ward; Anne G Wheaton; Janet B Croft
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-10-28       Impact factor: 17.586

5.  Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

Authors:  Silvio Danese; Matthieu Allez; Ad A van Bodegraven; Iris Dotan; Javier P Gisbert; Ailsa Hart; Peter L Lakatos; Fernando Magro; Laurent Peyrin-Biroulet; Stefan Schreiber; Dino Tarabar; Stephan Vavricka; Jonas Halfvarson; Séverine Vermeire
Journal:  Dig Dis       Date:  2019-02-06       Impact factor: 2.404

6.  Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Authors:  Paul Rutgeerts; Christopher Gasink; Daphne Chan; Yinghua Lang; Paul Pollack; Jean-Frederic Colombel; Douglas C Wolf; Douglas Jacobstein; Jewel Johanns; Philippe Szapary; Omoniyi J Adedokun; Brian G Feagan; William J Sandborn
Journal:  Gastroenterology       Date:  2018-08-29       Impact factor: 22.682

7.  The irritable bowel syndrome: long-term prognosis and the physician-patient interaction.

Authors:  D M Owens; D K Nelson; N J Talley
Journal:  Ann Intern Med       Date:  1995-01-15       Impact factor: 25.391

8.  IBD and health-related quality of life -- discovering the true impact.

Authors:  Sanna Lönnfors; Severine Vermeire; Marco Greco; Daan Hommes; Chayim Bell; Luisa Avedano
Journal:  J Crohns Colitis       Date:  2014-03-21       Impact factor: 9.071

Review 9.  Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.

Authors:  Ferdinando D'Amico; Tommaso Lorenzo Parigi; Gionata Fiorino; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Therap Adv Gastroenterol       Date:  2019-05-16       Impact factor: 4.409

10.  Long-term Efficacy of Vedolizumab for Ulcerative Colitis.

Authors:  Edward V Loftus; Jean-Frédéric Colombel; Brian G Feagan; Severine Vermeire; William J Sandborn; Bruce E Sands; Silvio Danese; Geert R D'Haens; Arthur Kaser; Remo Panaccione; David T Rubin; Ira Shafran; Megan McAuliffe; Arpeat Kaviya; Serap Sankoh; Reema Mody; Brihad Abhyankar; Michael Smyth
Journal:  J Crohns Colitis       Date:  2017-04-01       Impact factor: 9.071

View more
  2 in total

Review 1.  Inflammatory Bowel Disease Nurse-Practical Messages.

Authors:  Chiara Rosso; Alami Aroussi Aaron; Angelo Armandi; Gian Paolo Caviglia; Marta Vernero; Giorgio Maria Saracco; Marco Astegiano; Elisabetta Bugianesi; Davide Giuseppe Ribaldone
Journal:  Nurs Rep       Date:  2021-04-01

2.  Evaluation of Anti-Inflammatory and Antioxidant Effectsof Chrysanthemum Stem and Leaf Extract on Zebrafish Inflammatory Bowel Disease Model.

Authors:  Yi Li; Xia-Jin Liu; Shu-Lan Su; Hui Yan; Sheng Guo; Da-Wei Qian; Jin-Ao Duan
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.